Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
News|Articles|October 13, 2026
NLA Fall Clinical Lipid Update: Key Insights for Pharmacists
Author(s)Luke Halpern, Associate Editor
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
Advertisement
Advertisement
Patient hesitancy was a recurring theme at the National Lipid Association (NLA) 2026 Fall Clinical Lipid Update, held October 2 through 4 in Orlando, Florida. Faculty tackled questions pharmacists hear daily: whether a statin will hurt memory, whether diet can replace medication, and whether a once-in-a-lifetime blood test matters.1,2
Related to this article
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Advertisement
Advertisement